For years it was believed that the immune system has a negative role in the recovery from neurodegenerative diseases, such as strokes. Now, a research team led by scholars from Sweden and Israel and backed by the EU, is reexamining this assumption.

NeuroPhage Pharmaceuticals, a privately held biotechnology company focused on the treatment and prevention of neurodegenerative diseases, announced that it has secured $9 million. The funding round that was completed by existing investors and private investors brings the total amount of equity capital raised by NeuroPhage since its inception in 2006 to $28.6 million. NeuroPhage, which […]

BG Negev Technologies and Applications, the technology transfer company of Ben Gurion University of the Negev, has raised $1 million from a US private equity fund, to develop therapies for neurodegenerative diseases. The funding will support a study conducted by the university’s Department of Immunology and Microbiology, which might be useful for prolonging lifespans for […]